Finch Therapeutics Group, INC
Market Movers (8-K)
Finch Therapeutics has announced its decision to delist from the Nasdaq and deregister its common stock with the SEC, citing cost savings and compliance burdens.
Worse than expected
Finch Therapeutics and the University of Minnesota won a patent infringement case against Ferring Pharmaceuticals, securing a $25 million upfront payment and $0.815 million in running royalties.
Better than expected
Finch Therapeutics Group, Inc. will be delisted from the Nasdaq Stock Market and its shares will begin trading on the over-the-counter market after the company was deemed to no longer have an operating business.
Worse than expected
Finch Therapeutics has received an additional delisting notice from Nasdaq due to its failure to maintain the required market value of publicly held shares, and is requesting a transfer to the Nasdaq Capital Market.
Worse than expected
Finch Therapeutics has been notified by Nasdaq that it is not in compliance with audit committee composition requirements following a director's resignation.
Worse than expected
Finch Therapeutics has been notified by Nasdaq that it may be delisted due to concerns about its operating business status, prompting an appeal from the company.
Worse than expected
Delay expected
Quarterly Earnings (10-Q)
Finch Therapeutics continues to pursue intellectual property monetization after ceasing clinical development, reporting a net loss of $4.834 million for the quarter ended June 30, 2024, but also securing a favorable jury verdict in a patent infringement case.
Capital raise
Worse than expected
Finch Therapeutics continues its strategic shift towards realizing the value of its intellectual property, reporting a net loss of $3.876 million for Q1 2024.
Delay expected
Better than expected
Annual Reports (10-K)
Finch Therapeutics has filed an amendment to its annual report on Form 10-K to include information typically found in its proxy statement and required certifications.
Delay expected
10-K: Finch Therapeutics Shifts Focus to IP Monetization After Trial Discontinuation, Faces Delisting Risk
Finch Therapeutics has discontinued its Phase 3 clinical trial and is now focusing on monetizing its intellectual property, while also facing potential delisting from the Nasdaq.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
Director Jeffery Smisek reports gifting of Finch Therapeutics Group, Inc. common stock, both directly and indirectly through his spouse.
Director Jeffery Smisek reports a gift of 3,750 shares and the distribution of 18,254 shares to himself and 18,254 shares to his spouse from Flight Partners Management LLC.
Director Jeffery Smisek reports selling shares of Finch Therapeutics Group, Inc. on March 28, 2024.